Abstract
Although immunosuppressed patients may be more prone to SARS-CoV-2 infection with atypical presentation, long-term immunosuppression therapy may provide some sort of protection for severe clinical complications of COVID-19. The interaction between immunosuppression and new antiviral drugs in the treatment of transplanted patients contracting COVID-19 has not yet been fully investigated. Moreover, data regarding the optimal management of these patients are still very limited. We report a case of the successful recovery from severe COVID-19 of a kidney-transplanted patient treated with hydroxychloroquine, lopinavir/ritonavir, steroid, and tocilizumab.
Keywords:
COVID-19; coronavirus; immunosuppression; kidney transplantation; pandemic; tocilizumab.
© 2020 Wiley Periodicals LLC.
MeSH terms
-
Antibodies, Monoclonal, Humanized / therapeutic use*
-
Antiviral Agents / therapeutic use
-
COVID-19 / diagnosis
-
COVID-19 / immunology
-
COVID-19 / therapy*
-
COVID-19 / virology
-
Drug Therapy, Combination / methods
-
Female
-
Graft Rejection / immunology
-
Graft Rejection / prevention & control
-
Heparin, Low-Molecular-Weight / therapeutic use
-
Humans
-
Hydroxychloroquine / therapeutic use
-
Immunosuppression Therapy / adverse effects
-
Immunosuppressive Agents / adverse effects*
-
Kidney Transplantation / adverse effects*
-
Lopinavir / therapeutic use
-
Lung / diagnostic imaging
-
Middle Aged
-
Prednisolone / therapeutic use
-
Respiration, Artificial
-
Ritonavir / therapeutic use
-
SARS-CoV-2 / immunology*
-
SARS-CoV-2 / isolation & purification
-
Severity of Illness Index
-
Tomography, X-Ray Computed
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal, Humanized
-
Antiviral Agents
-
Heparin, Low-Molecular-Weight
-
Immunosuppressive Agents
-
Lopinavir
-
Hydroxychloroquine
-
Prednisolone
-
tocilizumab
-
Ritonavir